Psoriasis Market Size in Global Industry : Development, Research and Forecast 2019

ResearchMoz presents professional and in-depth study of "Competitor Landscape: Psoriasis".

Summary

Sociable Pharmas Treatment Landscape contains evaluations of ongoing development activities within the Psoriasis (PsO) market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher -
- Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted Sociable Pharmas view of the disease landscape

Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1978213

- Landscape Updates: Order of Entry analysis, detailing timeline forecasts for each drug in Phase II development or higher; Timeline forecasts for each approved products lifecycle management initiatives; Market Entry & Direction of Travel positioning analysis for pipeline & currently approved therapies
- Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
- Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019

Key Highlights

- Certolizumab pegol may find a niche in PsO patients looking to conceive, due to its global approval for use in women of childbearing age
- Novartis seeks to identify additional points of differentiation for secukinumab vs. competing biologics by further exploring efficacy and safety in pediatrics and alternative dosing formulations & strategies
- BMS-986165 could become the first TYK-2 inhibitor to be approved for PsO, pending positive data from the recently registered Phase III trials.

Scope

- The briefing is based on Sociable Pharmas analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
- Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix
- Forecasts are presented in pipeline forecast figures & detailed tables
- Market Entry & Direction of Travel positioning analysis for pipeline & currently approved therapies is also provided.

View Complete TOC with tables & Figures @ https://www.researchmoz.us/competitor-landscape-psoriasis-report.html/toc

Reasons to buy

- Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
- Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
- Reviews ongoing lifecycle management strategies for existing players in the market
- A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.

Companies mentioned
Novan
Novartis
Noxopharm
Nuevolution
Ortho Dermatologics
Pfizer
Polichem S.A.
Promius Pharma
Prothena Corporation
Realm Therapeutics
Reata Pharmaceuticals
Rigel
Saniona
Sareum
Sienna Biopharmaceuticals
Sun Pharma
Syntrix
Takeda
Theramab
Tianjin Hemay Bio-Tech
UCB

Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1978213

Valeant Pharmaceuticals
Vitae Pharmaceuticals
XenoPort
Zai Lab
Ziarco Pharma

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/